JP2013522231A5 - - Google Patents

Download PDF

Info

Publication number
JP2013522231A5
JP2013522231A5 JP2012557263A JP2012557263A JP2013522231A5 JP 2013522231 A5 JP2013522231 A5 JP 2013522231A5 JP 2012557263 A JP2012557263 A JP 2012557263A JP 2012557263 A JP2012557263 A JP 2012557263A JP 2013522231 A5 JP2013522231 A5 JP 2013522231A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
influenza virus
immunizing
reducing end
rha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012557263A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522231A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/027993 external-priority patent/WO2011112871A1/en
Publication of JP2013522231A publication Critical patent/JP2013522231A/ja
Publication of JP2013522231A5 publication Critical patent/JP2013522231A5/ja
Pending legal-status Critical Current

Links

JP2012557263A 2010-03-11 2011-03-10 インフルエンザのためのワクチン Pending JP2013522231A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31310110P 2010-03-11 2010-03-11
US61/313,101 2010-03-11
PCT/US2011/027993 WO2011112871A1 (en) 2010-03-11 2011-03-10 Vaccines for pandemic influenza

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016037168A Division JP2016104815A (ja) 2010-03-11 2016-02-29 インフルエンザのためのワクチン

Publications (2)

Publication Number Publication Date
JP2013522231A JP2013522231A (ja) 2013-06-13
JP2013522231A5 true JP2013522231A5 (https=) 2014-04-24

Family

ID=44170437

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012557263A Pending JP2013522231A (ja) 2010-03-11 2011-03-10 インフルエンザのためのワクチン
JP2016037168A Pending JP2016104815A (ja) 2010-03-11 2016-02-29 インフルエンザのためのワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016037168A Pending JP2016104815A (ja) 2010-03-11 2016-02-29 インフルエンザのためのワクチン

Country Status (13)

Country Link
US (1) US20110305748A1 (https=)
EP (1) EP2544718A1 (https=)
JP (2) JP2013522231A (https=)
KR (1) KR20130048208A (https=)
CN (1) CN102946900A (https=)
AU (1) AU2011224245B2 (https=)
BR (1) BR112012022939A2 (https=)
CA (1) CA2792369A1 (https=)
EA (1) EA201290897A1 (https=)
MX (1) MX2012010472A (https=)
NZ (1) NZ602217A (https=)
SG (1) SG183514A1 (https=)
WO (1) WO2011112871A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012141984A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
PL2811981T3 (pl) * 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
JP5944210B2 (ja) * 2012-04-18 2016-07-05 一般財団法人化学及血清療法研究所 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子が組み込まれたb5r遺伝子欠損組換えワクシニアウイルス
EP3041478A4 (en) * 2013-09-05 2017-04-26 Immune Design Corp. Vaccine compositions for drug addiction
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
CN111375055B (zh) * 2020-02-20 2021-09-03 陈宛莎 一种2019-nCoV亚单位疫苗组合物及其免疫方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4876197A (en) 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4925791A (en) 1984-07-20 1990-05-15 Celltech Limited Eucaryotic expression vectors
US5352449A (en) 1986-05-30 1994-10-04 Cambridge Biotech Corporation Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0382271B1 (en) 1989-02-04 1994-12-21 Akzo Nobel N.V. Tocols as adjuvant in vaccine
JP3723231B2 (ja) 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト アジュバント
US6022726A (en) 1992-02-03 2000-02-08 Palese; Peter Genetically engineered attenuated viruses
US5273965A (en) 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
MX9304089A (es) 1992-07-08 1994-01-31 Schering Corp Uso de gm-csf como una vacuna adyuvante.
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DE9319879U1 (de) 1993-12-23 1994-03-17 Ems-Inventa AG, Zürich Sequentiell Coextrudierte Kühlflüssigkeitsleitung
US5718904A (en) 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US20030045492A1 (en) 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
GB9809666D0 (en) 1998-05-06 1998-07-01 Isis Innovation Modified viruses
HK1039072A1 (zh) 1998-05-07 2002-04-12 科里克萨有限公司 佐剂组合物及其使用方法
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US20060024670A1 (en) 2004-05-18 2006-02-02 Luke Catherine J Influenza virus vaccine composition and methods of use
EP3332803B1 (en) 2004-06-01 2021-09-08 Icahn School of Medicine at Mount Sinai Genetically engineered swine influenza virus and uses thereof
WO2006088481A2 (en) 2005-02-15 2006-08-24 Mount Sinai School Of Medicine Of New York University Genetically engineered equine influenza virus and uses thereof
HRP20140488T1 (hr) * 2006-07-17 2014-07-04 Glaxosmithkline Biologicals S.A. Cjepivo protiv influence
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PT2468300T (pt) * 2006-09-26 2018-01-30 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
US8202967B2 (en) * 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
JP2007314538A (ja) * 2007-05-23 2007-12-06 Protein Sciences インフルエンザ血球凝集素多価ワクチンの製造方法
WO2009035528A2 (en) 2007-09-07 2009-03-19 University Of Georgia Research Foundation, Inc. Synthetic lipid a derivative
WO2009092038A1 (en) 2008-01-16 2009-07-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Influenza dna vaccination and methods of use thereof
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂

Similar Documents

Publication Publication Date Title
JP2013522231A5 (https=)
Goff et al. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses
JP6185548B2 (ja) インフルエンザワクチンの製造方法
HRP20190876T1 (hr) Novi adjuvantirani pripravci
Isakova-Sivak et al. Influenza vaccine: Progress in a vaccine that elicits a broad immune response
Ghendon et al. Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines
IL321503A (en) Recombinant virus, composition comprising the same, and uses thereof
RU2015132962A (ru) Иммуногенные композиции на основе вируса гриппа и их применение
WO2010036948A3 (en) Dna vaccine against influenza virus and prime boost method
Noh et al. Influenza vaccines: unmet needs and recent developments
Chua et al. Inactivated influenza vaccine that provides rapid, innate-immune-system-mediated protection and subsequent long-term adaptive immunity
JP2011525911A5 (https=)
Schotsaert et al. Inactivated influenza virus vaccines: the future of TIV and QIV
RU2011117167A (ru) Вакцинная композиция против гриппа
US10548965B2 (en) Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian H5N1 influenza
US10925957B2 (en) Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza
RU2016111704A (ru) Производные дезоксинойиримицина и способы их применения
BRPI0918806A2 (pt) composição compreendendo quitosana para administração ocular de vaninas em aves
BR112012022939A2 (pt) composição farmacêutica para uso em um método de imunização de um indivíduo em necessidade do mesmo contra um vírus influenza
WO2017053413A1 (en) Vaccines intelligently produced by epitope recombination (viper) for influenza
CN106999570B (zh) 含至少一种流感病毒的中和性结合分子的佐剂组合物及含该佐剂组合物的疫苗组合物
JP2016534062A5 (https=)
JP2016520077A5 (https=)
RU2014140168A (ru) Улучшенная вакцинация против гриппа
JP2009518410A5 (https=)